Akari Therapeutics Plc ADR (CLA)
XBER 
Summary
CLA Chart
Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript
Akari Therapeutics, Plc ( AKTX ) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head of Oncology Conference Call Participants Jenene Thomas Presentation Jenene Thomas Okay. We are ready to get started, and welcome, everyone, to the Akari Therapeutics Corporate Update Webcast.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Akari Therapeutics, PLC (NASDAQ:AKTX) , relating to its proposed merger with Peak Bio, Inc. Under the terms of the agreement, Akari shareholders are expected to own approximately 52% of the combined company.
Akari Therapeutics Plc ADR (CLA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Akari Therapeutics Plc ADR ever had a stock split?
Akari Therapeutics Plc ADR Profile
| - Industry | - Sector | Abizer Gaslightwala CEO | XBER Exchange | US00972G2075 ISIN |
| GB Country | 8 Employees | - Last Dividend | 17 Aug 2023 Last Split | 21 Sep 2015 IPO Date |
Overview
Akari Therapeutics, Plc is a forward-thinking clinical-stage biopharmaceutical company primarily engaged in the discovery and development of innovative treatments for a range of autoimmune and inflammatory diseases. With its foundations deeply rooted in cutting-edge scientific research, Akari is dedicated to addressing some of the most challenging medical conditions with limited treatment options available. Positioning itself as a leader in the field, the company's strategic focus on complement inhibitors showcases its commitment to pioneering approaches that have the potential to transform the lives of patients worldwide. Based in the bustling city of London in the United Kingdom, Akari Therapeutics leverages its geographical location to foster collaborations and access a wide network of research and development opportunities to advance its mission.
Products and Services
- Nomacopan - Akari’s flagship product candidate, nomacopan, stands as a beacon of hope for patients suffering from a variety of severe autoimmune and inflammatory diseases. This second-generation complement inhibitor is designed to halt the inflammatory and prothrombotic activities that are characteristic of disorders such as paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. By targeting the underlying mechanisms that drive these conditions, nomacopan could significantly improve the quality of life for those affected.
- PASylated-Nomacopan - In its relentless pursuit of innovation, Akari is also advancing a pre-clinical program focused on the development of a long-acting version of nomacopan. This PASylated-nomacopan variant is engineered to extend the molecule's half-life, thereby offering a potentially transformative treatment option for geographic atrophy secondary to dry age-related macular degeneration. This advancement underscores Akari’s dedication to pushing the boundaries of science to uncover new solutions for diseases with substantial unmet needs.
Contact Information
